Biomedicine Key Laboratory of Shaanxi Province, Northwest University, No. 229 Taibai North Road, Xi'an 710069, People's Republic of China.
J Ethnopharmacol. 2011 Nov 18;138(2):279-85. doi: 10.1016/j.jep.2011.09.030. Epub 2011 Oct 5.
Er-Zhi-Wan (EZW), a classic Chinese formulation, which contains Fructus Ligustri Lucidi (FLL) and Herba Ecliptae (HE). EZW is widely used to prevent and treat various kidney diseases for its actions of nourishing the kidney and strengthening tendon and bone. Although recent reports indicate that EZW restrains osteoclastic bone resorption, its effects on the protection against define OVX-induced bone loss in mature rats have not been systematically investigated.
Sixty 3-month-old female Sprague-Dawley rats were randomly assigned into sham-operated group (Sham) and five OVX subgroups, OVX with vehicle (OVX); OVX with Estradiol Valerate (EV, 0.4 mg/kg body weight/day); OVX with EZW of graded doses (9.0, 4.5, or 2.25 g/kg/day). Daily oral administration of EV and EZW on 5th week for 26 weeks. Bone turnover markers (Serum alkaline phosphatase (ALP), bone-specific alkaline phosphatase (BALP), osteocalcin (OCN), deoxypyridinoline (DPD)), other parameters, including serum calcium (S-Ca), serum phosphorus (S-P), urine calcium (U-Ca), phosphorus (U-P), and bone mineral density (BMD) of the femur, 4th lumbar vertebra and tibia, bone biomechanical properties and trabecular microarchitecture parameters were measured.
Administration of EZW could significantly prevent ovariectomy-induced bone loss, biomechanical reduction, deterioration of trabecular microarchitecture and the body weight gain without affecting the weight of the uterus, and increased S-Ca, S-P levels, decreased level of bone turnover markers and U-Ca, U-P levels in ovariectomized rats.
The present study indicated that EZW had a definite antiosteoporotic effect without hyperplastic effect on uterus, and it might be a potential alternative medicine for treatment of postmenopausal osteoporosis.
二至丸（EZW）是一种经典的中药配方，包含女贞子（FLL）和墨旱莲（HE）。EZW 因其补肾强筋壮骨的作用而被广泛用于预防和治疗各种肾脏疾病。尽管最近的报道表明 EZW 抑制破骨细胞骨吸收，但它对保护成熟大鼠去卵巢诱导的骨丢失的影响尚未得到系统研究。
60 只 3 月龄雌性 Sprague-Dawley 大鼠随机分为假手术组（Sham）和 5 个去卵巢亚组，即去卵巢+溶剂（OVX）；去卵巢+戊酸雌二醇（EV，0.4mg/kg 体重/天）；EZW 分级剂量（9.0、4.5 或 2.25g/kg/天）。第 5 周开始每日口服 EV 和 EZW，共 26 周。骨转换标志物（血清碱性磷酸酶（ALP）、骨碱性磷酸酶（BALP）、骨钙素（OCN）、脱氧吡啶啉（DPD））、其他参数，包括血清钙（S-Ca）、血清磷（S-P）、尿钙（U-Ca）、磷（U-P）、股骨、第 4 腰椎和胫骨的骨密度（BMD）、骨生物力学特性和小梁微结构参数。
EZW 可显著预防去卵巢引起的骨丢失、生物力学降低、小梁微结构恶化和体重增加，而不影响子宫重量，并增加 S-Ca、S-P 水平，降低骨转换标志物水平和 U-Ca、U-P 水平去卵巢大鼠。
本研究表明，EZW 具有明确的抗骨质疏松作用，对子宫无增生作用，可能是治疗绝经后骨质疏松症的一种潜在替代药物。
